Free Trial
NASDAQ:SLRX

Salarius Pharmaceuticals Q3 2023 Earnings Report

Salarius Pharmaceuticals logo
$0.61 +0.00 (+0.26%)
Closing price 07/18/2025 03:56 PM Eastern
Extended Trading
$0.63 +0.02 (+2.80%)
As of 07/18/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Salarius Pharmaceuticals EPS Results

Actual EPS
-$5.20
Consensus EPS
-$8.56
Beat/Miss
Beat by +$3.36
One Year Ago EPS
N/A

Salarius Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Salarius Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Salarius Pharmaceuticals' Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Salarius Pharmaceuticals Earnings Headlines

Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 0.1% - Should You Buy?
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Salarius Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Salarius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Salarius Pharmaceuticals and other key companies, straight to your email.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals (NASDAQ:SLRX) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel targeted therapies for patients with rare and difficult-to-treat cancers. The company’s research platform focuses on epigenetic regulators and cyclin-dependent kinases (CDKs), with the aim of modulating key pathways involved in tumor growth, survival, and metastasis. Salarius leverages proprietary drug discovery technologies to advance small-molecule inhibitors designed to address unmet medical needs in oncology.

The company’s lead asset, seclidemstat, is an oral lysine-specific demethylase 1 (LSD1) inhibitor being evaluated in multiple Phase 2 clinical trials for Ewing sarcoma and other solid tumors. In preclinical studies, seclidemstat has demonstrated the ability to impede tumor cell proliferation and reduce metastatic potential by altering the epigenetic landscape of cancer cells. Additionally, Salarius is developing fadraciclib, a potent CDK2/9 inhibitor targeting hematologic malignancies such as chronic lymphocytic leukemia and acute myeloid leukemia, with data supporting its role in disrupting transcriptional regulation in tumor cells.

Founded in 2017 and headquartered in Houston, Texas, Salarius Pharmaceuticals was established to harness cutting-edge science for the benefit of patients facing aggressive cancers. The company operates a lean organizational structure, partnering with leading academic institutions and Contract Research Organizations (CROs) to optimize clinical trial design and accelerate program timelines. This collaborative approach has enabled Salarius to advance multiple programs into the clinic while maintaining operational efficiency.

Salarius is led by a seasoned management team with extensive experience in drug development, regulatory affairs, and corporate strategy. Under the leadership of Chief Executive Officer Pete Hooper, the company has strengthened its clinical pipeline and expanded its strategic partnerships. Salarius intends to continue advancing its key programs through late-stage clinical development and, ultimately, to deliver novel therapeutic options to patients in the United States and select international markets.

View Salarius Pharmaceuticals Profile

More Earnings Resources from MarketBeat